09:44:52 EDT Sat 15 Jun 2024
Enter Symbol
or Name
USA
CA



Q:CAPR - CAPRICOR THERAPEUTICS INC - http://www.capricor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CAPR - Q0.15.00·6.250.55.17-0.12-2.3218.61,0691,5455.25  5.3487  5.038.2212  2.6818:15:19Jun 1115 min RT 2¢

Recent Trades - Last 10 of 1545
Time ETExPriceChangeVolume
18:15:19Q5.03-0.265
17:56:15Q5.02-0.273,000
17:45:20Q5.04-0.251
17:11:12Q5.04-0.255
17:10:51Q5.02-0.275
17:10:31Q5.04-0.255
17:10:04Q5.04-0.252
17:09:22Q5.04-0.2515
17:08:47Q5.04-0.255
17:08:25Q5.04-0.255

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-11 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
2024-06-04 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
2024-05-13 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-09 09:15U:CAPRNews ReleaseCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
2024-05-08 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
2024-05-06 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
2024-04-24 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
2024-03-21 08:30U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Investor Conferences
2024-03-06 08:30U:CAPRNews ReleaseCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2024-02-29 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-27 08:30U:CAPRNews ReleaseCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
2024-02-22 08:30U:CAPRNews ReleaseCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
2024-02-20 08:30U:CAPRNews ReleaseCapricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
2024-01-24 09:15U:CAPRNews ReleaseCapricor Therapeutics Announces Collaboration with the National Institutes of Health ‚  for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
2023-12-11 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
2023-11-14 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-07 09:15U:CAPRNews ReleaseCapricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
2023-10-19 16:01U:CAPRNews ReleaseCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
2023-10-10 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
2023-09-29 07:36U:CAPRNews ReleaseCapricor Therapeutics Announces $23 Million Registered Direct Offering